Review





Similar Products

96
Santa Cruz Biotechnology non targeting scrambled control sirna
Hypoxia‐driven ferroptosis is MARCH5‐dependent. (A) Bone marrow‐derived primary neutrophils were treated with CHX for the indicated time, together with or without hypoxia treatment. Relative intensity of FSP1 to β‐tubulin was analyzed ( n = 4 independent experiments). (B) The mRNA expression levels of Aifm2 gene in hypoxia‐treated bone marrow‐derived primary neutrophils were measured using qPCR ( n = 4 independent experiments). (C) Immunoblotting analysis of hypoxia‐treated bone marrow‐derived primary neutrophils treated with MG132 (10 μM), 3‐MA (5 mM), or Baf A1 (0.1 μM) for 6 h, and the relative protein level was quantified ( n = 4 independent experiments). (D) The potential E3 ligases were predicted using UbiBrowser database, and the co‐immunoprecipitation (co‐IP; with anti‐FLAG) and immunoblotting analysis using protein lysates of HEK293T cells transfected with the indicated plasmids. WCL, whole cell lysates. (E) Co‐IP and immunoblotting analysis using protein lysates of bone marrow‐derived primary neutrophils treated with hypoxia. (F) HEK293T cells were transfected with FLAG‐FSP1 and HA‐tagged WT ubiquitin (HA‐Ub), together with MYC‐EV or MYC‐MARCH5 for 24 h, followed by treatment with MG132 for 6 h, followed by co‐immunoprecipitated with anti‐Flag beads and immunoblotted with anti‐HA antibody. (G) Bone marrow‐derived primary neutrophils were transfected with <t>Scr</t> <t>siRNA</t> or MARCH5‐specific siRNA for 24 h, followed by transfected with FLAG‐EV or FLAG‐FSP1 for 24 h; protein lysates were harvested after hypoxia treatment for 12 h and MG132 treatment for 6 h for IP (with anti‐FSP1) and immunoblotting analysis using indicated antibodies. Molecular weight markers are indicated on the left (kDa). All error bars represent the mean ± SD. p values were calculated using a two‐tailed Student's t ‐test. *** p < 0.001; ns, not significant.
Non Targeting Scrambled Control Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/Control+siRNA-A/pmc13749613-86-20-26
Average 96 stars, based on 1 article reviews
non targeting scrambled control sirna - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology negative control scrambled sirna
Relationship between MIF and TMED10. (A) Secretion of MIF was measured in HEK293T cells either untreated or treated with brefeldin A. (B) Secretion of MIF was measured in HEK293T cells untreated or treated with the indicated doses of probenecid. (C) GST or the indicated GST-TMED10 domains coupled to glutathione sepharose beads were incubated with whole cell lysates from HEK293T cells expressing Flag-MIF. Elutes were subjected to SDS-PAGE and immunoblotted with an anti-Flag antibody. (D) GST-MIF coupled to glutathione sepharose beads was incubated with whole cell lysate from HEK293T cells expressing GFP-TMED10 or GFP-TMED10(ΔCT). Elutes were subjected to SDS-PAGE and immunoblotted with anti-GFP antibody. (E) Secretion of MIF was measured in HEK293T cells expressing mock or GFP-TMED10. (F) Secretion of MIF was measured in HEK293T cells treated with control <t>siRNA</t> or siRNA targeting TMED10 for 72 h. (G) A crosslink assay was performed in HEK293T cells expressing GFP-TMED10 with mock or Flag-MIF to examine the oligomeric form of TMED10. (H) Secretion of Flag-MIF was measured in HEK293T cells expressing mock, RAB1A, 1B, and 2A.
Negative Control Scrambled Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/Control+siRNA-A/pmc13652084-151-19-23
Average 96 stars, based on 1 article reviews
negative control scrambled sirna - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology non targeting scrambled sirna
Relationship between MIF and TMED10. (A) Secretion of MIF was measured in HEK293T cells either untreated or treated with brefeldin A. (B) Secretion of MIF was measured in HEK293T cells untreated or treated with the indicated doses of probenecid. (C) GST or the indicated GST-TMED10 domains coupled to glutathione sepharose beads were incubated with whole cell lysates from HEK293T cells expressing Flag-MIF. Elutes were subjected to SDS-PAGE and immunoblotted with an anti-Flag antibody. (D) GST-MIF coupled to glutathione sepharose beads was incubated with whole cell lysate from HEK293T cells expressing GFP-TMED10 or GFP-TMED10(ΔCT). Elutes were subjected to SDS-PAGE and immunoblotted with anti-GFP antibody. (E) Secretion of MIF was measured in HEK293T cells expressing mock or GFP-TMED10. (F) Secretion of MIF was measured in HEK293T cells treated with control <t>siRNA</t> or siRNA targeting TMED10 for 72 h. (G) A crosslink assay was performed in HEK293T cells expressing GFP-TMED10 with mock or Flag-MIF to examine the oligomeric form of TMED10. (H) Secretion of Flag-MIF was measured in HEK293T cells expressing mock, RAB1A, 1B, and 2A.
Non Targeting Scrambled Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/Control+siRNA-A/10__1186_slash_s13058___026___02391___9-87-1-5
Average 96 stars, based on 1 article reviews
non targeting scrambled sirna - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology control scrambled sirna duplexes
Relationship between MIF and TMED10. (A) Secretion of MIF was measured in HEK293T cells either untreated or treated with brefeldin A. (B) Secretion of MIF was measured in HEK293T cells untreated or treated with the indicated doses of probenecid. (C) GST or the indicated GST-TMED10 domains coupled to glutathione sepharose beads were incubated with whole cell lysates from HEK293T cells expressing Flag-MIF. Elutes were subjected to SDS-PAGE and immunoblotted with an anti-Flag antibody. (D) GST-MIF coupled to glutathione sepharose beads was incubated with whole cell lysate from HEK293T cells expressing GFP-TMED10 or GFP-TMED10(ΔCT). Elutes were subjected to SDS-PAGE and immunoblotted with anti-GFP antibody. (E) Secretion of MIF was measured in HEK293T cells expressing mock or GFP-TMED10. (F) Secretion of MIF was measured in HEK293T cells treated with control <t>siRNA</t> or siRNA targeting TMED10 for 72 h. (G) A crosslink assay was performed in HEK293T cells expressing GFP-TMED10 with mock or Flag-MIF to examine the oligomeric form of TMED10. (H) Secretion of Flag-MIF was measured in HEK293T cells expressing mock, RAB1A, 1B, and 2A.
Control Scrambled Sirna Duplexes, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/Control+siRNA-B/pm42387534-80-2-13
Average 93 stars, based on 1 article reviews
control scrambled sirna duplexes - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Genechem non targeting scrambled sirna si nc
UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, <t>short</t> <t>hairpin</t> <t>RNA;</t> NC, negative control; OE, overexpression.
Non Targeting Scrambled Sirna Si Nc, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/control+non+targeting/pmc13203321-47-17-28
Average 86 stars, based on 1 article reviews
non targeting scrambled sirna si nc - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Eurofins scramble sirna
UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, <t>short</t> <t>hairpin</t> <t>RNA;</t> NC, negative control; OE, overexpression.
Scramble Sirna, supplied by Eurofins, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/sirna/pm42243281-232-1-4
Average 86 stars, based on 1 article reviews
scramble sirna - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Sangon Biotech scramble sirnas
UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, <t>short</t> <t>hairpin</t> <t>RNA;</t> NC, negative control; OE, overexpression.
Scramble Sirnas, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/sirna/pmc13014669-38-10-12
Average 86 stars, based on 1 article reviews
scramble sirnas - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Keygen Biotech non targeting scrambled sirna
UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, <t>short</t> <t>hairpin</t> <t>RNA;</t> NC, negative control; OE, overexpression.
Non Targeting Scrambled Sirna, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/6+dehydrogenase+encoded+mitochondria+nadh+rna+sequences+sirna+targeting/pm42107543-63-4-13
Average 86 stars, based on 1 article reviews
non targeting scrambled sirna - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Cohesion Biosciences scramble sirna
UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, <t>short</t> <t>hairpin</t> <t>RNA;</t> NC, negative control; OE, overexpression.
Scramble Sirna, supplied by Cohesion Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+sirnas/scramble+sirna/pm42098279-87-7-14
Average 86 stars, based on 1 article reviews
scramble sirna - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Hypoxia‐driven ferroptosis is MARCH5‐dependent. (A) Bone marrow‐derived primary neutrophils were treated with CHX for the indicated time, together with or without hypoxia treatment. Relative intensity of FSP1 to β‐tubulin was analyzed ( n = 4 independent experiments). (B) The mRNA expression levels of Aifm2 gene in hypoxia‐treated bone marrow‐derived primary neutrophils were measured using qPCR ( n = 4 independent experiments). (C) Immunoblotting analysis of hypoxia‐treated bone marrow‐derived primary neutrophils treated with MG132 (10 μM), 3‐MA (5 mM), or Baf A1 (0.1 μM) for 6 h, and the relative protein level was quantified ( n = 4 independent experiments). (D) The potential E3 ligases were predicted using UbiBrowser database, and the co‐immunoprecipitation (co‐IP; with anti‐FLAG) and immunoblotting analysis using protein lysates of HEK293T cells transfected with the indicated plasmids. WCL, whole cell lysates. (E) Co‐IP and immunoblotting analysis using protein lysates of bone marrow‐derived primary neutrophils treated with hypoxia. (F) HEK293T cells were transfected with FLAG‐FSP1 and HA‐tagged WT ubiquitin (HA‐Ub), together with MYC‐EV or MYC‐MARCH5 for 24 h, followed by treatment with MG132 for 6 h, followed by co‐immunoprecipitated with anti‐Flag beads and immunoblotted with anti‐HA antibody. (G) Bone marrow‐derived primary neutrophils were transfected with Scr siRNA or MARCH5‐specific siRNA for 24 h, followed by transfected with FLAG‐EV or FLAG‐FSP1 for 24 h; protein lysates were harvested after hypoxia treatment for 12 h and MG132 treatment for 6 h for IP (with anti‐FSP1) and immunoblotting analysis using indicated antibodies. Molecular weight markers are indicated on the left (kDa). All error bars represent the mean ± SD. p values were calculated using a two‐tailed Student's t ‐test. *** p < 0.001; ns, not significant.

Journal: Immunity, Inflammation and Disease

Article Title: MARCH5 Links Hypoxia to Neutrophil Ferroptosis in SLE via FSP1 Ubiquitination

doi: 10.1002/iid3.70583

Figure Lengend Snippet: Hypoxia‐driven ferroptosis is MARCH5‐dependent. (A) Bone marrow‐derived primary neutrophils were treated with CHX for the indicated time, together with or without hypoxia treatment. Relative intensity of FSP1 to β‐tubulin was analyzed ( n = 4 independent experiments). (B) The mRNA expression levels of Aifm2 gene in hypoxia‐treated bone marrow‐derived primary neutrophils were measured using qPCR ( n = 4 independent experiments). (C) Immunoblotting analysis of hypoxia‐treated bone marrow‐derived primary neutrophils treated with MG132 (10 μM), 3‐MA (5 mM), or Baf A1 (0.1 μM) for 6 h, and the relative protein level was quantified ( n = 4 independent experiments). (D) The potential E3 ligases were predicted using UbiBrowser database, and the co‐immunoprecipitation (co‐IP; with anti‐FLAG) and immunoblotting analysis using protein lysates of HEK293T cells transfected with the indicated plasmids. WCL, whole cell lysates. (E) Co‐IP and immunoblotting analysis using protein lysates of bone marrow‐derived primary neutrophils treated with hypoxia. (F) HEK293T cells were transfected with FLAG‐FSP1 and HA‐tagged WT ubiquitin (HA‐Ub), together with MYC‐EV or MYC‐MARCH5 for 24 h, followed by treatment with MG132 for 6 h, followed by co‐immunoprecipitated with anti‐Flag beads and immunoblotted with anti‐HA antibody. (G) Bone marrow‐derived primary neutrophils were transfected with Scr siRNA or MARCH5‐specific siRNA for 24 h, followed by transfected with FLAG‐EV or FLAG‐FSP1 for 24 h; protein lysates were harvested after hypoxia treatment for 12 h and MG132 treatment for 6 h for IP (with anti‐FSP1) and immunoblotting analysis using indicated antibodies. Molecular weight markers are indicated on the left (kDa). All error bars represent the mean ± SD. p values were calculated using a two‐tailed Student's t ‐test. *** p < 0.001; ns, not significant.

Article Snippet: For gene silencing, neutrophils were transfected with small interfering RNA (siRNA) targeting March5 (Cat: #sc‐149269, Santa Cruz Biotechnology) or a non‐targeting scrambled control siRNA (Cat: #sc‐37007, Santa Cruz Biotechnology) using Lipofectamine RNAiMAX(Cat: #13778150, Thermo Fisher Scientific).

Techniques: Derivative Assay, Expressing, Western Blot, Analysis, Co-Immunoprecipitation Assay, Transfection, Ubiquitin Proteomics, Immunoprecipitation, Molecular Weight, Two Tailed Test

Hypoxia‐driven ferroptosis is MARCH5‐dependent. (A–F) Bone marrow‐derived primary neutrophils were transfected with Scr siRNA or MARCH5‐specific siRNA for 24 h, and then cultured under normoxia or hypoxia with or without treatment with Erastin (A–C) or FSEN1 (D–F), and the rate of cell death was measured using the CCK‐8 assay (A, D), and the lipid ros (B, E) and 4‐HNE were detected (C, F) ( n = 4 independent experiments). All error bars represent the mean ± s.d. p values were calculated using a two‐tailed Student's t ‐test. *** p < 0.001; ns, not significant.

Journal: Immunity, Inflammation and Disease

Article Title: MARCH5 Links Hypoxia to Neutrophil Ferroptosis in SLE via FSP1 Ubiquitination

doi: 10.1002/iid3.70583

Figure Lengend Snippet: Hypoxia‐driven ferroptosis is MARCH5‐dependent. (A–F) Bone marrow‐derived primary neutrophils were transfected with Scr siRNA or MARCH5‐specific siRNA for 24 h, and then cultured under normoxia or hypoxia with or without treatment with Erastin (A–C) or FSEN1 (D–F), and the rate of cell death was measured using the CCK‐8 assay (A, D), and the lipid ros (B, E) and 4‐HNE were detected (C, F) ( n = 4 independent experiments). All error bars represent the mean ± s.d. p values were calculated using a two‐tailed Student's t ‐test. *** p < 0.001; ns, not significant.

Article Snippet: For gene silencing, neutrophils were transfected with small interfering RNA (siRNA) targeting March5 (Cat: #sc‐149269, Santa Cruz Biotechnology) or a non‐targeting scrambled control siRNA (Cat: #sc‐37007, Santa Cruz Biotechnology) using Lipofectamine RNAiMAX(Cat: #13778150, Thermo Fisher Scientific).

Techniques: Derivative Assay, Transfection, Cell Culture, CCK-8 Assay, Two Tailed Test

Relationship between MIF and TMED10. (A) Secretion of MIF was measured in HEK293T cells either untreated or treated with brefeldin A. (B) Secretion of MIF was measured in HEK293T cells untreated or treated with the indicated doses of probenecid. (C) GST or the indicated GST-TMED10 domains coupled to glutathione sepharose beads were incubated with whole cell lysates from HEK293T cells expressing Flag-MIF. Elutes were subjected to SDS-PAGE and immunoblotted with an anti-Flag antibody. (D) GST-MIF coupled to glutathione sepharose beads was incubated with whole cell lysate from HEK293T cells expressing GFP-TMED10 or GFP-TMED10(ΔCT). Elutes were subjected to SDS-PAGE and immunoblotted with anti-GFP antibody. (E) Secretion of MIF was measured in HEK293T cells expressing mock or GFP-TMED10. (F) Secretion of MIF was measured in HEK293T cells treated with control siRNA or siRNA targeting TMED10 for 72 h. (G) A crosslink assay was performed in HEK293T cells expressing GFP-TMED10 with mock or Flag-MIF to examine the oligomeric form of TMED10. (H) Secretion of Flag-MIF was measured in HEK293T cells expressing mock, RAB1A, 1B, and 2A.

Journal: Autophagy Reports

Article Title: TRPML3 and TRPML1/3 differentially regulate unconventional MIF secretion through TMED10 and secretory autophagy

doi: 10.1080/27694127.2026.2740425

Figure Lengend Snippet: Relationship between MIF and TMED10. (A) Secretion of MIF was measured in HEK293T cells either untreated or treated with brefeldin A. (B) Secretion of MIF was measured in HEK293T cells untreated or treated with the indicated doses of probenecid. (C) GST or the indicated GST-TMED10 domains coupled to glutathione sepharose beads were incubated with whole cell lysates from HEK293T cells expressing Flag-MIF. Elutes were subjected to SDS-PAGE and immunoblotted with an anti-Flag antibody. (D) GST-MIF coupled to glutathione sepharose beads was incubated with whole cell lysate from HEK293T cells expressing GFP-TMED10 or GFP-TMED10(ΔCT). Elutes were subjected to SDS-PAGE and immunoblotted with anti-GFP antibody. (E) Secretion of MIF was measured in HEK293T cells expressing mock or GFP-TMED10. (F) Secretion of MIF was measured in HEK293T cells treated with control siRNA or siRNA targeting TMED10 for 72 h. (G) A crosslink assay was performed in HEK293T cells expressing GFP-TMED10 with mock or Flag-MIF to examine the oligomeric form of TMED10. (H) Secretion of Flag-MIF was measured in HEK293T cells expressing mock, RAB1A, 1B, and 2A.

Article Snippet: For knockdown experiments, siRNA targeting human TMED10 (BIONEER, 10,972–1), human ATG5 (BIONEER, 9474–1), human SYT5 (BIONEER, 6861–1), and a negative control scrambled siRNA (Santa Cruz Biotechnology, sc-37007) were used.

Techniques: Incubation, Expressing, SDS Page, Control

Effect of autophagy on MIF secretion. (A) HeLa cells expressing GFP-LC3 and mCherry-MIF were treated with cold digitonin (50 µg/ml) and imaged by fluorescence microscopy. (B) Secretion of MIF was measured in HEK293T cells either untreated or treated with 10 μM SAR405. (C) Secretion of MIF was measured in HEK293T cells treated with control siRNA or siRNA targeting ATG5 for 72 h. (D) Secretion of MIF was measured in HEK293T cells either untreated or treated with 100 nM bafilomycin A1. (E) Secretion of MIF was measured in HEK293T cells treated with control siRNA or siRNA targeting SYT5 for 48 h. Knockdown efficiency was confirmed by immunoblotting for SYT5. (F) Secretion of Flag-MIF was measured in HEK293T cells expressing mock or GFP-SEC22B. (G) HeLa cells expressing GFP-SEC22B and mCherry-MIF were treated with cold digitonin (50 µg/ml) and imaged by fluorescence microscopy. (H, upper) HeLa cells co-expressing GFP-MIF and Flag-VAMP4 were treated with cold digitonin (50 µg/ml), immunostained with an anti-Flag antibody, and imaged by fluorescence microscopy. (H, lower) HeLa cells expressing GFP-VAMP8 and mCherry-MIF were treated with cold digitonin (50 µg/ml) and imaged by fluorescence microscopy.

Journal: Autophagy Reports

Article Title: TRPML3 and TRPML1/3 differentially regulate unconventional MIF secretion through TMED10 and secretory autophagy

doi: 10.1080/27694127.2026.2740425

Figure Lengend Snippet: Effect of autophagy on MIF secretion. (A) HeLa cells expressing GFP-LC3 and mCherry-MIF were treated with cold digitonin (50 µg/ml) and imaged by fluorescence microscopy. (B) Secretion of MIF was measured in HEK293T cells either untreated or treated with 10 μM SAR405. (C) Secretion of MIF was measured in HEK293T cells treated with control siRNA or siRNA targeting ATG5 for 72 h. (D) Secretion of MIF was measured in HEK293T cells either untreated or treated with 100 nM bafilomycin A1. (E) Secretion of MIF was measured in HEK293T cells treated with control siRNA or siRNA targeting SYT5 for 48 h. Knockdown efficiency was confirmed by immunoblotting for SYT5. (F) Secretion of Flag-MIF was measured in HEK293T cells expressing mock or GFP-SEC22B. (G) HeLa cells expressing GFP-SEC22B and mCherry-MIF were treated with cold digitonin (50 µg/ml) and imaged by fluorescence microscopy. (H, upper) HeLa cells co-expressing GFP-MIF and Flag-VAMP4 were treated with cold digitonin (50 µg/ml), immunostained with an anti-Flag antibody, and imaged by fluorescence microscopy. (H, lower) HeLa cells expressing GFP-VAMP8 and mCherry-MIF were treated with cold digitonin (50 µg/ml) and imaged by fluorescence microscopy.

Article Snippet: For knockdown experiments, siRNA targeting human TMED10 (BIONEER, 10,972–1), human ATG5 (BIONEER, 9474–1), human SYT5 (BIONEER, 6861–1), and a negative control scrambled siRNA (Santa Cruz Biotechnology, sc-37007) were used.

Techniques: Expressing, Fluorescence, Microscopy, Control, Knockdown, Western Blot

UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, short hairpin RNA; NC, negative control; OE, overexpression.

Journal: Experimental and Therapeutic Medicine

Article Title: CDX2-UPK1B-PIK3IP1-PI3K/AKT signaling axis regulates gastric cancer cell invasion and migration and influences patient prognosis

doi: 10.3892/etm.2026.13179

Figure Lengend Snippet: UPK1B drives GC cell invasion and migration in a PI3K/AKT-dependent manner. (A) Gene set enrichment analysis indicated that genes upregulated in the UPK1B-high group were enriched in the PI3K/AKT pathway. (B) Protein levels of UPK1B in GC cell lines. (C) Knockdown of UPK1B reduced PI3K/AKT activation in MKN45 cells. Silencing UPK1B suppressed the (D) migration/invasion capacity and (E) wound closure rate of MKN45 cells. (F) Overexpression of UPK1B enhanced PI3K/AKT pathway activation in AGS cells, which was attenuated by the PI3K inhibitor LY294002. Inhibition of PI3K/AKT signaling reversed UPK1B-induced (G) migration/invasion capacity and (H) wound closure rate of AGS cells. UPK1B, uroplakin 1B; GC, gastric cancer; p-, phosphorylated; sh, short hairpin RNA; NC, negative control; OE, overexpression.

Article Snippet: Cells were also transfected with small interfering RNAs (siRNAs) targeting CDX2 or PIK3IP1 , with a universal non-targeting scrambled siRNA (si-NC) as the negative control , obtained from GeneChem, Inc. For UPK1B and CDX2 overexpression, the p-TSB-CMV-UPK1B and p-TSB-CMV-CDX2 expression vectors [Shanghai Genomeditech Co., Ltd.] and the corresponding empty p-TSB-CMV vector (negative control) were used.

Techniques: Migration, Knockdown, Activation Assay, Over Expression, Inhibition, shRNA, Negative Control

CDX2 acts as a transcriptional repressor of UPK1B and its high expression is associated with favorable prognosis of patients with GC. (A) Venn diagram showing overlapping predicted transcriptional regulators of UPK1B from ChEA and ChEA3 databases. (B) Knockdown of CDX2 in AGS cells resulted in increased UPK1B (C) mRNA and (D) protein expression. (E) Overexpression of CDX2 in MKN45 cells reduced UPK1B protein levels. Data from (F) The Cancer Genome Atlas Stomach Adenocarcinoma cohort and (G) the Kaplan-Meier plotter database indicated that high CDX2 expression was associated with improved prognosis of patients with GC. UPK1B, uroplakin 1B; GC, gastric cancer; si, small interfering RNA; NC, negative control; OE, overexpression; HR, hazard ratio; CDX2, caudal-related homeobox transcription factor 2; ChEA, ChIP-X Enrichment Analysis.

Journal: Experimental and Therapeutic Medicine

Article Title: CDX2-UPK1B-PIK3IP1-PI3K/AKT signaling axis regulates gastric cancer cell invasion and migration and influences patient prognosis

doi: 10.3892/etm.2026.13179

Figure Lengend Snippet: CDX2 acts as a transcriptional repressor of UPK1B and its high expression is associated with favorable prognosis of patients with GC. (A) Venn diagram showing overlapping predicted transcriptional regulators of UPK1B from ChEA and ChEA3 databases. (B) Knockdown of CDX2 in AGS cells resulted in increased UPK1B (C) mRNA and (D) protein expression. (E) Overexpression of CDX2 in MKN45 cells reduced UPK1B protein levels. Data from (F) The Cancer Genome Atlas Stomach Adenocarcinoma cohort and (G) the Kaplan-Meier plotter database indicated that high CDX2 expression was associated with improved prognosis of patients with GC. UPK1B, uroplakin 1B; GC, gastric cancer; si, small interfering RNA; NC, negative control; OE, overexpression; HR, hazard ratio; CDX2, caudal-related homeobox transcription factor 2; ChEA, ChIP-X Enrichment Analysis.

Article Snippet: Cells were also transfected with small interfering RNAs (siRNAs) targeting CDX2 or PIK3IP1 , with a universal non-targeting scrambled siRNA (si-NC) as the negative control , obtained from GeneChem, Inc. For UPK1B and CDX2 overexpression, the p-TSB-CMV-UPK1B and p-TSB-CMV-CDX2 expression vectors [Shanghai Genomeditech Co., Ltd.] and the corresponding empty p-TSB-CMV vector (negative control) were used.

Techniques: Expressing, Knockdown, Over Expression, Small Interfering RNA, Negative Control

UPK1B activates PI3K/AKT signaling by antagonizing the inhibitory regulator PIK3IP1 in gastric cancer cells. (A) Venn diagram showing that PIK3IP1 was identified as a putative UPK1B-interacting partner based on BioGRID and HIPPIE protein-protein interaction databases. (B) UPK1B and PIK3IP1 co-localized in the cytoplasm and plasma membrane of MKN45 cells. (C) Interaction between UPK1B and PIK3IP1 in MKN45 cells. (D) Knockdown of PIK3IP1 in MKN45 cells. (E) Silencing PIK3IP1 in UPK1B-knockdown MKN45 cells restored PI3K/AKT pathway activation. Knockdown of PIK3IP1 reversed the decrease in (F) migration/invasion and (G) wound-healing capacity in UPK1B-silenced MKN45 cells. UPK1B, uroplakin 1B; p-, phosphorylated; si, small interfering RNA; sh, short hairpin RNA; NC, negative control; PIK3IP1, PI3K inhibitor interacting protein 1; HIPPIE, Human Integrated Protein-Protein Interaction Reference; IP, immunoprecipitation.

Journal: Experimental and Therapeutic Medicine

Article Title: CDX2-UPK1B-PIK3IP1-PI3K/AKT signaling axis regulates gastric cancer cell invasion and migration and influences patient prognosis

doi: 10.3892/etm.2026.13179

Figure Lengend Snippet: UPK1B activates PI3K/AKT signaling by antagonizing the inhibitory regulator PIK3IP1 in gastric cancer cells. (A) Venn diagram showing that PIK3IP1 was identified as a putative UPK1B-interacting partner based on BioGRID and HIPPIE protein-protein interaction databases. (B) UPK1B and PIK3IP1 co-localized in the cytoplasm and plasma membrane of MKN45 cells. (C) Interaction between UPK1B and PIK3IP1 in MKN45 cells. (D) Knockdown of PIK3IP1 in MKN45 cells. (E) Silencing PIK3IP1 in UPK1B-knockdown MKN45 cells restored PI3K/AKT pathway activation. Knockdown of PIK3IP1 reversed the decrease in (F) migration/invasion and (G) wound-healing capacity in UPK1B-silenced MKN45 cells. UPK1B, uroplakin 1B; p-, phosphorylated; si, small interfering RNA; sh, short hairpin RNA; NC, negative control; PIK3IP1, PI3K inhibitor interacting protein 1; HIPPIE, Human Integrated Protein-Protein Interaction Reference; IP, immunoprecipitation.

Article Snippet: Cells were also transfected with small interfering RNAs (siRNAs) targeting CDX2 or PIK3IP1 , with a universal non-targeting scrambled siRNA (si-NC) as the negative control , obtained from GeneChem, Inc. For UPK1B and CDX2 overexpression, the p-TSB-CMV-UPK1B and p-TSB-CMV-CDX2 expression vectors [Shanghai Genomeditech Co., Ltd.] and the corresponding empty p-TSB-CMV vector (negative control) were used.

Techniques: Clinical Proteomics, Membrane, Knockdown, Activation Assay, Migration, Small Interfering RNA, shRNA, Negative Control, Immunoprecipitation